Meeting brief

Pre-Series B introduction — Contoso BioWorks

Company: Contoso BioWorks; contoso-bio.example
Primary attendee: Dr. Tomás Esquivel; Co-founder & CEO
Objective: Earn the right to be in the room when the Series B advisor decision is made — through credibility on scale-up economics and the founder-led process the bulge brackets won't run.

Also attending

Dr. Lin Zhao · Co-founder & CTO

Executive summary

Tomás is 12 months from a likely Series B and is being pitched constantly. He doesn't need money or noise — he needs an advisor who treats the science seriously and can frame the scale-up economics story that will define the round. The outcome to drive: leave with agreement to a focused 'pre-process' diagnostic — a 4-week piece of work that positions the firm as the de-facto Series B advisor without forcing the conversation.

Key talking points

For the lift up

01Lead with scale-up unit economics — the Series B narrative he doesn't yet own
02Reference the March scaffold engineering paper as proof of platform thesis
03Surface the strategic-on-cap-table conflict ahead of any B-round process
04Frame a 4-week pre-process diagnostic, not a pitch for advisor mandate
05Acknowledge the London office as optionality, not distraction

Company context

a US East Coast synthetic biology platform building engineered enzymes for industrial-scale carbon capture and specialty chemicals. university spin-out 2022, $24M Series A in October led by Tyrell Ventures with Stark Capital and a strategic from a Tier 1 specialty chemicals strategic. ~28 employees, mostly PhDs. Pre-revenue with two paid technical evaluations live. Strong IP on the directed-evolution platform; the unproven question — and the central Series B question — is scale-up unit economics.

Attendee profile

Tomás Esquivel — CEO: a top-tier US research university structural biologist, ran a lab at a leading US research university. Soft-spoken but exacting; goes quiet when he hears something imprecise. Public position: optimises for partners 'who treat the science seriously, not just commercially'. He is the face; he is also the gatekeeper for who gets near the round.

Lin Zhao — CTO: Runs the platform technically; rarely in commercial meetings, present today because the relationship matters. Will judge the firm on whether anyone in the room can hold a real technical conversation.

Group dynamic: Tomás decides; Lin can veto. Win Lin's respect in this meeting and the Series B mandate becomes the firm's to lose.

Strategic signals

Series A announced Oct 2025
Summarytrade-press coverage emphasised platform-not-product positioning, key for premium Series B multiple.
Hired former a publicly-listed synthetic biology platform head of process development in Feb
Summarybuilding commercial-readiness, exact signal a B-round investor wants.
Tomás co-authored peer-reviewed journal paper in March on scaffold engineering
Summarypublic proof point the round will be built on.
Quietly opened small London office in Q1
Summaryopens EU funding access and a non-US bidder for the round.
a Tier 1 specialty chemicals strategic on the cap table
Summarysets up an obvious strategic conflict to navigate at Series B.

Likely priorities

Validating the platform with credible industrial partners ahead of Series B (~12–18 months out).
Building the scale-up economics narrative — the make-or-break Series B question.
Preserving scientific direction; not getting pulled into bespoke customer projects too early.
Choosing a Series B advisor 6–9 months ahead of process — quietly, without a beauty parade.

Conversation angles

Lead with the science — reference the peer-reviewed journal paper specifically, ask one real question about the scaffold work.
Position the firm as a long-cycle advisor, not a deal-shop; reference a specific 18+ month relationship that paid off at the right round.
Bring a named technical sponsor in writing afterwards — Lin will respect 'I want our biocatalysis lead to meet you' more than any commercial framing.
Be explicit about what the firm doesn't know on carbon capture economics — don't bluff a thesis you haven't built.

Discovery questions

01Where does the platform genuinely outperform today, and where is it still earning the right to be called a platform?
02When you imagine the Series B story 12 months from now, what do you most need an advisor to have already done?
03How are you thinking about the trade-off between bespoke partner projects and protecting the core platform roadmap?
04How does Tyrell Ventures want the next round structured — strategic-led, financial-led, or a barbell?
05Is there a specific technical or commercial gap in your story today where an outside team could meaningfully accelerate you in the next two quarters?

Opportunities

4-week pre-process diagnostic — scale-up economics narrative + investor map — £60–90k, partner-led.
Series B sell-side advisory mandate at the right moment — £600k–1.2M plus success — primary outcome of this relationship.
Quiet strategic introductions to two industrial partners with stated decarbonisation roadmaps — relationship currency now.
Optional EU non-dilutive funding workstream via the London office — small but signals long-term partner.

Risks & sensitivities

He will be wary of any meeting that moves too quickly toward a Series B mandate conversation — earn it, don't ask for it.
Tyrell Ventures's preference is keeping strategic investors out of the cap table until B — do not signal investment intent.
Avoid framing Contoso BioWorks as 'a CRO with a platform' — that is the exact mischaracterisation he pushes back on publicly.
a Tier 1 specialty chemicals strategic on the cap table — tread carefully if any firm client competes in adjacent application areas.

Suggested next steps

01Send 1-page pre-process diagnostic outline — within 5 days — corporate finance partner.
02Schedule technical session: head of biocatalysis with Lin — within 3 weeks — partner to broker.
03Share two anonymised Series B economics narratives the firm has built for analogous platforms — within 10 days — partner.

Suggested follow-up email

Subject

Contoso BioWorks — proposed next step

Dear Tomás,

Thank you for the time today, and for letting Lin be part of the conversation.

Your framing of the scaffold work and how it constrains the directed-evolution loop was the most useful thing I've heard on this topic in months. Rather than try to scope a commercial relationship at this stage, we'd propose a 4-week pre-process diagnostic — focused entirely on the scale-up economics narrative your Series B will be built on. No mandate conversation, no commercial commitment either way. Just an honest piece of work that leaves you better prepared whether or not we ever work together on the round itself.

I'll send a one-page outline within the week. No pressure on timing.
With respect,
[Your name]